News & Articles

FDA Official Guidelines On January 31, 2024, the FDA CBER officially released the "Human Gene Therapy Products Incorporating Human Genome...

Since December 2023, there have been several positive updates about drugs targeting MSLN. On December 19th, RemeGen announced that the...

Since its debut in 2016, base editing technology has opened up new perspectives and methods for drug development with its...

Colorectal cancer (CRC) is recognized as one of the most common and life-threatening malignancies, with an increasing proportion of advanced...

Through decades of rapid development, gene editing technology has officially entered the CRISPR 2.0 era, with new technologies such as...

Neuroendocrine neoplasms/tumors (NENs or NETs) are rare tumors that originate from specialized cells called neuroendocrine cells. These cells have characteristics...

Immunotherapy is an essential option for current disease treatment. However, most patients fail to respond adequately to existing immunotherapies, such...

Speaker Dr. Manhee Suh, Co-founder & CTO, KACTUS What's Inside When dealing with solid tumors lacking specific biomarkers, the effectiveness...

Overview By leveraging its sophisticated ‘Structure Aided Design and Multiplex Screening (SAMS™)’ platform, along with extensive experience in process development...

Overview AccuBase™ is a new generation base editing tool independently developed by Base Therapeutics with exclusive global IP rights. AccuBase™ enzyme is...

On November 13, 2023, Legend Biotech officially announced that its wholly-owned subsidiary, Legend Biotech Ireland Limited, has entered into an...

KACTUS and Base Therapeutics announced their new strategic partnership to facilitate global manufacturing and sales of the GMP-grade base editor...